Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

Authors Lopez-Campos JL, Calero-Acuña C, Márquez-Martín E, Quintana Gallego E, Carrasco-Hernández L, Abad Arranz M, Ortega Ruiz F

Received 22 January 2017

Accepted for publication 18 May 2017

Published 23 June 2017 Volume 2017:12 Pages 1867—1876

DOI https://doi.org/10.2147/COPD.S132962

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Jose Luis Lopez-Campos,1,2 Carmen Calero-Acuña,1,2 Eduardo Márquez-Martín,1 Esther Quintana Gallego,1,2 Laura Carrasco-Hernández,1 Maria Abad Arranz,1 Francisco Ortega Ruiz1,2

1Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IBiS), Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain; 2Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

Objective: The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic obstructive pulmonary disease (COPD). Here, we systematically review the current knowledge on double bronchodilation for the treatment of COPD, with a specific focus on its efficacy versus placebo and/or monotherapy bronchodilation.
Methods: A systematic review of clinical trials investigating LABA/LAMA combination therapies was conducted. Articles were retrieved from PubMed, Embase, and Scopus on June 26, 2016. We specifically selected clinical trials with a randomized controlled or crossover design published in any scientific journal showing the following characteristics: 1) comparison of different LABA/LAMA combinations in a single inhaler for patients with COPD, 2) dose approved in Europe, and 3) focus on efficacy (versus placebo and/or bronchodilator monotherapy) in terms of lung function, respiratory symptoms, or exacerbations.
Results: We analyzed 26 clinical trials conducted on 24,338 patients. All LABA/LAMA combinations were consistently able to improve lung function compared with both placebo and bronchodilator monotherapy. Improvements in symptoms were also consistent versus placebo, showing some lack of correlation for some clinical end points and combinations versus monotherapy bronchodilation. Albeit being an exploratory end point, exacerbations showed an improvement with LABA/LAMA combinations over placebo in some trials; however, scarce information was available in comparison with bronchodilator monotherapy in most studies.
Conclusion: Our data show consistent improvements for LABA/LAMA combinations, albeit with some variability (depending on the clinical end point, the specific combination, and the comparison group). Clinicians should be aware that these are average differences. All treatments should be tailored at the individual level to optimize clinical outcomes.

Keywords: COPD, bronchodilators, efficacy, systematic review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Seasonal variability in clinical care of COPD outpatients: results from the Andalusian COPD audit

López-Campos JL, Abad Arranz M, Calero-Acuña C, Romero-Valero F, Ayerbe-García R, Hidalgo-Molina A, Aguilar-Pérez-Grovas RI, García-Gil F, Casas-Maldonado F, Caballero-Ballesteros L, Sánchez-Palop M, Pérez-Tejero D, Segado Soriano A, Calvo-Bonachera J, Hernández-Sierra B, Doménech A, Arroyo-Varela M, González-Vargas F, Cruz-Rueda JJ

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:785-792

Published Date: 3 March 2017

Determinants for changing the treatment of COPD: a regression analysis from a clinical audit

López-Campos JL, Abad Arranz M, Calero Acuña C, Romero Valero F, Ayerbe García R, Hidalgo Molina A, Aguilar Perez-Grovas RI, García Gil F, Casas Maldonado F, Caballero Ballesteros L, Sánchez Palop M, Pérez-Tejero D, Segado A, Calvo Bonachera J, Hernández Sierra B, Doménech A, Arroyo Varela M, González Vargas F, Cruz Rueda JJ

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1171-1178

Published Date: 2 June 2016

Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis

Lopez-Campos JL, Fernandez-Villar A, Calero-Acuña C, Represas-Represas C, Lopez-Ramírez C, Fernández VL, Soler-Cataluña JJ, Casamor R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:975-984

Published Date: 27 May 2015

Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium

Lopez-Campos JL, Calero C, Lopez-Ramirez C, Asensio-Cruz MI, Márquez-Martín E, Ortega-Ruiz F

Patient Preference and Adherence 2015, 9:95-104

Published Date: 17 January 2015

Symptom variability in COPD: a narrative review

Lopez-Campos JL, Calero C, Quintana-Gallego E

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:231-238

Published Date: 7 May 2013

Modified BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake

José Luis Lopez-Campos, Pilar Cejudo, Eduardo Marquez, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:133-140

Published Date: 4 May 2010